Physician profile
Steven Wayne Ditto
NPI 1568455772
$4,919.37
in general payments reported to CMS, 2019-2025
35 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $315 · 2021: $411 · 2022: $801 · 2023: $928 · 2024: $925 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $939.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $686.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $645.04 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $476.26 | 2019-2025 | |
| Novo Nordisk INC | $246.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $213.42 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.14 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.67 | 2020-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $122.43 | 2023-2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $108.17 | 2023-2024 | Qelbree, Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $105.90 | 2022-2025 | |
| Lilly USA, LLC | $103.91 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $102.51 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Sanofi-Aventis U.S. LLC | $85.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $77.91 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $73.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $69.24 | 2022 | |
| Sanofi Pasteur INC. | $53.71 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $46.35 | 2022-2023 | |
| Allergan, INC. | $44.16 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $41.06 | 2022 | |
| Amgen INC. | $40.46 | 2019-2025 | Otezla, Repatha |
| Ucb, INC. | $36.79 | 2021 | |
| Dexcom, INC. | $32.01 | 2022-2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $30.29 | 2021 | |
| Ironshore Pharmaceuticals INC. | $29.84 | 2019 | |
| Amarin Pharma, INC. | $27.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.16 | 2019 | |
| Astellas Pharma US INC | $21.57 | 2019 | |
| Averitas Pharma INC. | $20.10 | 2025 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.89 | 2019 | |
| Mylan Specialty L.P. | $17.09 | 2024 | Yupelri |
| Sobi, INC | $16.09 | 2023 | |
| Eisai INC. | $16.04 | 2021 | |
| Vyera Pharmaceuticals, LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ditto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.